By providing a measure of systemic inflammation, white blood cell (WBC) count may be a stable, well-standardized, widely available, and inexpensive way to independently predict cardiovascular events and death in postmenopausal women, according to findings from the Women's Health Initiative Observational Study.
By providing a measure of systemic inflammation, white blood cell (WBC) count may be a stable, well-standardized, widely available, and inexpensive way to independently predict cardiovascular events and death in postmenopausal women, according to findings from the Women's Health Initiative Observational Study.
The prospective cohort study-which was the first to assess WBC count as a predictor of cardiovascular disease (CVD) events in healthy women while controlling for C-reactive protein (CRP)-involved 40 US clinical centers and over 72,000 postmenopausal women free of CVD and cancer at baseline. The researchers found that women with a WBC count greater than 6.7 × 109 cells/L were more than twice as likely to die of coronary heart disease (CHD) as women with a WBC count of 2.5–4.7 × 109 cells/L (hazard ratio 2.36; 95% confidence interval [CI], 1.51–3.68). In addition, they had a 40% higher risk for nonfatal myocardial infarction, a 46% higher risk for stroke, and a 50% higher risk for total mortality.
The results demonstrate that WBC count is an independent predictor of CHD risk and may help pinpoint high-risk women who are not currently being identified with more traditional CVD risk factors.
Study shows hormone therapy offers lasting benefits for women over 65
September 12th 2024A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.
Read More